Select a medication above to begin.
Tasmar
tolcapone
Black Box Warnings .
Hepatotoxicity
potentially fatal, acute fulminant hepatic failure risk; reserve for pts on l-dopa/carbidopa w/ sx fluctuations who are not candidates or not responding to alternative adjunct tx; D/C tx if no substantial clinical benefit after 3wk; avoid use if hepatic dz or 2 AST/ALT values >ULN; caution if severe dyskinesia or dystonia; monitor AST/ALT at baseline, q2-4wk x6mo after start or incr. dose, then periodically; D/C if AST/ALT >2xULN or clinical s/sx of hepatic failure, do not restart due to incr. hepatic injury risk
Adult Dosing .
Dosage forms: TAB: 100 mg
Parkinson dz, adjunct tx
- [100 mg PO tid]
- Max: 600 mg/day; Info: use w/ carbidopa/levodopa; D/C if no benefit at max dose after 3wk; taper dose gradually to D/C
renal dosing
- [see below]
- CrCl >25: no adjustment; CrCl <25: not defined, caution advised
- HD/PD: not defined
hepatic dosing
- [see below]
- elev. AST and/or ALT, hepatic impairment: contraindicated
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.